IL23A and inflammatory bowel disease: Conversely, in IBD, both ustekinumab and anti-IL-23p19 antibodies are effective, whereas clinical trials of anti-IL17A agents have demonstrated a lack of efficacy and even worsening in some cases [1,2,3,4,12].